VolitionRx Limited (NYSE American: VNRX) has announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. This application builds on the company’s existing Nu.Q NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality.
The company’s CE-Marked automated Nu.Q NETs assay and recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions. Volition is actively seeking partnerships with global health organizations, pharmaceutical developers, NGOs, and distribution partners to support field trials, manufacturing scale-up, and potential deployment in outbreak zones.
The implications of this announcement are significant. Ebola outbreaks often occur in areas with limited healthcare infrastructure, where rapid diagnosis and triage are critical for controlling the spread of the virus. Current diagnostic methods can be expensive, require specialized equipment, and may not be readily available in remote settings. Volition’s technology, if successfully developed and deployed, could offer a rapid, low-cost alternative that can be used at the bedside, potentially improving patient outcomes and aiding in outbreak management.
This patent application underscores Volition’s commitment to expanding its intellectual property portfolio in infectious disease diagnostics. The company’s Nu.Q platform has already shown promise in detecting and monitoring diseases associated with NETosis, such as sepsis. By targeting Ebola, Volition is addressing a critical unmet need in global health security.
For more details, the full press release is available at https://ibn.fm/UOWP1. Volition is a multi-national company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring.
